Evidence map›Paper›PMID 35350791›Full record

ArticleAsiaIntervention2022

Long-term mortality after pulmonary artery denervation stratified by baseline functional class in patients with pulmonary arterial hypertension: Long-term mortality after PADN stratified by functional class.

Han Zhang, Jing Kan, Caojing Zhang, Zhenweng Yang, Heping Gu, Fenling Fan, Hong Gu, Qiguang Wang, Juan Zhang, Dujiang Xie and 4 more

Abstract read
In one paragraph

Article in AsiaIntervention, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Pulmonary hypertension.Nature reviews. Disease primers · 2024
    Review
  4. Article
  5. Article
  6. Article
  7. Current status of pulmonary artery denervation.Frontiers in cardiovascular medicine · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Han ZhangNanjing First Hospital, Nanjing Medical University, Nanjing, China.
Jing KanNanjing First Hospital, Nanjing Medical University, Nanjing, China.
Caojing ZhangGuangdong Provincial Peoples Hospital, Guangdong Academy of Medical Sciences, Guangdong Cardiovascular Institute, Guangzhou, China.
Zhenweng YangGeneral Hospital of Tianjin Medical University, Tianjin, China.
Heping GuThe First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
Fenling FanFirst Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China.
Hong GuBeijing Anzhen Hospital, Beijing, China.
Qiguang WangGeneral Hospital of Northern Theater Command, Shenyang, China.
Juan ZhangNanjing First Hospital, Nanjing Medical University, Nanjing, China.
Dujiang XieNanjing First Hospital, Nanjing Medical University, Nanjing, China.
Gangcheng ZhangZhongNan Hospital of Wuhan University, Wuhan, China.
Xiaomei GuoTongji Hospital, Huazhong University of Science and Technology, Wuhan, China.
Yuehui YinThe Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Shao-Liang ChenNanjing First Hospital, Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: This study aimed to assess the long-term effects of pulmonary artery denervation (PADN) on mortality in patients with pulmonary arterial hypertension (PAH). Methods and results: Between March 2012 and March 2018, a total of 120 patients with PAH, who underwent PADN treatment and were prospectively followed up, were analysed. Patients were classified into World Health Organization (WHO) Functional Class I and II (FC 1-2; n=46) and Functional Class III and IV (FC 3-4; n=74) according to their FC prior to PADN. The primary endpoint was lung transplantation-free mortality until March 2021. The secondary endpoint was a change in the six-minute walk distance (6MWD). During the median of 4.8 years of follow-up, 23 (19.2%) patients died, predominantly from the FC 3-4 group (25.7%), compared to 8.7% in the FC 1-2 group (p=0.034). The mortality rate at one year (2.2% vs 12.2%, p=0.087) and three years (6.5% vs 17.6%, p=0.102) was numerically low in the FC 1-2 group versus the FC 3-4 group, respectively. The median net increase of 6MWD was +29 m in the FC 1-2 group, compared to +60.5 m in the FC 3-4 group (p=0.037). Conclusions: PADN results in significant improvements in survival at long-term follow-up, especially in patients with PAH in FC 3-4. This study was the continuation of the PADN-1 study which was registered at URL: http://www.chictr.trc.com.cn. Unique identifier: chiCTR-ONC-12002085.

Identifiers

PMID35350791
PMCPMC8922462

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.